Professional Documents
Culture Documents
maas-2024-treatment-for-childhood-apraxia-of-speech-past-present-and-future
maas-2024-treatment-for-childhood-apraxia-of-speech-past-present-and-future
maas-2024-treatment-for-childhood-apraxia-of-speech-past-present-and-future
At the time of the first Apraxia Kids Research Sym- research agenda. Since then, and since the initiation of
posium (AKRS) in 2002, no cohesive research community Apraxia Kids’ annual Research Grant competition in 2007,
existed dedicated to the study of childhood apraxia of the CAS treatment literature has grown rapidly, as illus-
speech (CAS). That first research symposium, and Apraxia trated by a simple PubMed search with the search term
Kids (then known as the Childhood Apraxia of Speech “childhood apraxia of speech treatment” (see Figure 1).
Association of North America) more generally, was instru-
mental in bringing together scientists with research interests
in or related to CAS and identifying priorities for a Purpose
Journal of Speech, Language, and Hearing Research 1–26 Copyright © 2024 The Author 1
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Downloaded from: https://pubs.asha.org 5.210.215.88 on 06/08/2024, Terms of Use: https://pubs.asha.org/pubs/rights_and_permissions
Figure 1. Number of peer-reviewed articles published on the topic of childhood apraxia of speech (CAS) treatment since 1990 (source:
PubMed; search term “childhood apraxia of speech treatment”). Key events that stimulated CAS treatment research are indicated on this
timeline. AKRS = Apraxia Kids Research Symposium; ASHA = American Speech-Language-Hearing Association.
treatment research and thus optimize clinical practice and big-picture, “bird’s-eye level” perspective of the current
outcomes for children with CAS. As a record of AKRS evidence base and trends. In the spirit of the AKRS, occa-
2022, this review article serves as a mile marker and sign- sional references to presentations at the 2022 symposium
post along the road of CAS treatment research and has the and other recent conferences are included to highlight
following specific purposes: emerging developments and help readers anticipate publi-
cations in the near future by identifying research groups
1. To introduce basic concepts of clinical trials for
engaged in cutting-edge CAS treatment research.
those in the CAS community who are less familiar
with such research. This introduction will help The literature review is structured along four main
appreciate the overview to follow. treatment research questions, each involving different
research designs and approaches, and each related to an
2. To review and synthesize the CAS treatment litera-
element of the PICO1 question format: (a) “Does Treat-
ture and identify gaps and trends.
ment X work?”, (b) “Does Treatment X work better than
3. To formulate some possible future directions for the Treatment Y?”, (c) “For whom does Treatment X
CAS treatment research agenda. work?”, (d) “What does ‘work’ mean, anyway?” This
organization is for expository purposes and does not
Scope and Organization imply independence. Clearly, the question of whether a
treatment works is intertwined with the question of for
An important caveat is in order at the outset: An whom it works, and the question of what “work” means
overview and synthesis of the by-now sizable and complex is integral to all others. Moreover, undoubtedly, readers
CAS treatment research literature required some selection will identify additional gaps and future directions. Never-
and structure. Therefore, although an attempt was made theless, the hope is that this review and structure
to offer broad coverage, this is a narrative rather than a
systematic or scoping review (see Murray et al., 2014, for 1
PICO: P = Population; I = Intervention; C = Comparison (no or
a systematic review). As such, the review is not exhaustive other intervention); O = Outcome (e.g., For children with CAS [P],
and does not discuss studies in detail but rather provides a does Treatment X [I] or Treatment Y [C] lead to better outcomes [O]?)
future. As will become clear, the road has been long, and as the likely importance of practice in naturalistic set-
while there is much road yet ahead of us, it is important tings (M. E. Morley, 1969) and emphasizing movement
to appreciate how far we have already come. sequences and visual cues (J. Rosenbek et al., 1974; Yoss
& Darley, 1974). Of course, these authors recognized that
A Brief Historical Context: The Early Days their recommendations were necessarily tentative and
were offered “not so much as answers to the sometimes
In the early days of CAS treatment (arbitrarily cho- perplexing questions of apraxia therapeutics but as devel-
sen here as pre-1990), important initial guiding light in the opmental milestones so that we can look back one day
darkness involved case reports and clinical expert opinion and see how far we have come” (J. C. Rosenbek &
by such luminaries as Muriel Morley (M. Morley et al., Wertz, 1976, p. 197). Correspondingly, there was recogni-
1955; M. E. Morley, 1969), Jay Rosenbek (J. Rosenbek tion of the need for further research, as expressed clearly
et al., 1974; J. C. Rosenbek & Wertz, 1972), and Kathe by J. C. Rosenbek and Wertz (1972, p. 32): “Results of
Yoss (Yoss & Darley, 1974). These researchers made rec- experimental therapy with these children are badly needed.”
ommendations based on their own and others’ clinical And so the stage was set. Fast forward to the present day
experience, evidence from adults with apraxia of speech, for a look at how far we have come and what our next
and case reports (i.e., mostly Level 4 evidence) for a pop- milestones for CAS treatment development may be.
ulation that back then was even less well understood
than it is today. It is not surprising that some recommen- Does Treatment X Work?
dations and opinions may no longer be considered Approaches and Evidence
appropriate, such as suggestions to begin by targeting
“production of one phonetic sound in isolation” (M. E. This first question is perhaps the most basic and the
Morley, 1969, p. 161), the pessimistic notion that one most commonly addressed in treatment research: Does
“attempts to teach a child to speak will produce little Treatment X work? This section first provides a brief narra-
result” (M. Morley et al., 1955, p. 467), and recommen- tive review of CAS treatment approaches (“Treatments X”)
dations that “compensatory behaviors such as equal and the current evidence base, followed by discussion of
stress and the use of pauses to break up phrases and sen- some emerging trends and directions for future research.
tences may be appropriate” (J. C. Rosenbek & Wertz,
1972, p. 32) or to begin therapy “with mirror work and The Present
all kinds of tongue and lip movements” (Yoss & Darley,
1974, p. 30). Rather, it is perhaps surprising how pre- Today, there are quite a few specific intervention
scient these authors were in their recommendations, such approaches designed specifically for children with CAS
Figure 4. Hypothesized pathway of how a treatment effects change in a clinical goal at the WHO ICF Participation level (after Czajkowski
et al., 2015; see also Figure 2). Colors correspond to levels of the WHO ICF as in Figure 3 (red = Body Structure/Function, blue = Activity,
green = Participation, yellow = Environmental Factors, orange = Personal Factors). In this example, the (more distal) clinical goal is commu-
nicative participation (Baylor & Darling-White, 2020) measured on a caregiver-reported instrument (e.g., Thomas-Stonell et al., 2012). Barriers
include intelligibility and comprehensibility (Activity), willingness to take a risk and engage in a communicative situation (Personal Factors),
and listener effort and willingness and ability to accommodate the speaker (Environmental Factors). Note that speech accuracy (the clinical
goal in Figure 2) is now relegated to a more proximal focus of treatment among others that may require additional treatments or compo-
nents; integral stimulation is used here as one example of an impairment-focused intervention. Note further that different elements within a
domain (focus of treatment, barrier) may influence each other as well. To be clear, these examples are hypotheses that require further test-
ing, but this pathway illustrates how (elements of) treatments could be added to maximize the clinical goal of communicative participation.
AAC = augmentative and alternative communication; ICF = International Classification of Functioning, Disability and Health; WHO = World
Health Organization.